Neurogenic erectile dysfunction: State of the art!

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Erection is a neurovascular event characterised by the tumescence of the cavernous bodies that relies upon integration of neural and humoral mechanisms and requires the participation ofautonomic and somatic nerves and the integration of numerous spinal and supraspinal sites.Erectile dysfunction (ED) is a highly prevalent problem increasing with age, as well as being a major sexual concern for men. Neurogenic ED can be broadly defined as an inability to sustain or maintain a penile erection owing to a neurologic impairment, either centrally or peripherally or both. Neurological disorders may cause an interruption of the long spinal tracts between cortex and sacral cord or the pelvic autonomic nerves interfering with genital engorgement, erection, ejaculation, and climax.They can also challenge the physical ability to embrace, stimulate, engage in intercourse, and maintain urinary and bowel continence during sexual activity. Such factors may lead to a primary or secondary neurogenic ED.Patients with neurological disorders, especially if male and young, might consider their sexual dysfunction as the most devastating aspect. Significant advances in the pharmacological treatment of ED have occurred in recent years, most notably after the introduction of Sildenafil, the first oral selective phosphodiesterase type 5 inhibitor.Nevertheless, many other oral, local and surgical treatments are available and their efficacy and safety depend on the specific cases.This chapter is aimed at evaluating the current advances in neurogenic ED management taking into account its complex pathophysiology and targets for treatment.

Original languageEnglish
Title of host publicationErectile Dysfunction: Causes, Risk Factors and Management
PublisherNova Science Publishers, Inc.
Pages97-127
Number of pages31
ISBN (Print)9781619423169
Publication statusPublished - 2012

Fingerprint

Erectile Dysfunction
Nervous System Diseases
Penile Erection
Phosphodiesterase 5 Inhibitors
Autonomic Pathways
Ejaculation
Aptitude
Sexual Behavior
Nervous System
Spinal Cord
Therapeutics
Pharmacology
Safety

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Calabrò, R. S. (2012). Neurogenic erectile dysfunction: State of the art! In Erectile Dysfunction: Causes, Risk Factors and Management (pp. 97-127). Nova Science Publishers, Inc..

Neurogenic erectile dysfunction : State of the art! / Calabrò, Rocco Salvatore.

Erectile Dysfunction: Causes, Risk Factors and Management. Nova Science Publishers, Inc., 2012. p. 97-127.

Research output: Chapter in Book/Report/Conference proceedingChapter

Calabrò, RS 2012, Neurogenic erectile dysfunction: State of the art! in Erectile Dysfunction: Causes, Risk Factors and Management. Nova Science Publishers, Inc., pp. 97-127.
Calabrò RS. Neurogenic erectile dysfunction: State of the art! In Erectile Dysfunction: Causes, Risk Factors and Management. Nova Science Publishers, Inc. 2012. p. 97-127
Calabrò, Rocco Salvatore. / Neurogenic erectile dysfunction : State of the art!. Erectile Dysfunction: Causes, Risk Factors and Management. Nova Science Publishers, Inc., 2012. pp. 97-127
@inbook{34e549ef2f544a24b137827b4da3c5bf,
title = "Neurogenic erectile dysfunction: State of the art!",
abstract = "Erection is a neurovascular event characterised by the tumescence of the cavernous bodies that relies upon integration of neural and humoral mechanisms and requires the participation ofautonomic and somatic nerves and the integration of numerous spinal and supraspinal sites.Erectile dysfunction (ED) is a highly prevalent problem increasing with age, as well as being a major sexual concern for men. Neurogenic ED can be broadly defined as an inability to sustain or maintain a penile erection owing to a neurologic impairment, either centrally or peripherally or both. Neurological disorders may cause an interruption of the long spinal tracts between cortex and sacral cord or the pelvic autonomic nerves interfering with genital engorgement, erection, ejaculation, and climax.They can also challenge the physical ability to embrace, stimulate, engage in intercourse, and maintain urinary and bowel continence during sexual activity. Such factors may lead to a primary or secondary neurogenic ED.Patients with neurological disorders, especially if male and young, might consider their sexual dysfunction as the most devastating aspect. Significant advances in the pharmacological treatment of ED have occurred in recent years, most notably after the introduction of Sildenafil, the first oral selective phosphodiesterase type 5 inhibitor.Nevertheless, many other oral, local and surgical treatments are available and their efficacy and safety depend on the specific cases.This chapter is aimed at evaluating the current advances in neurogenic ED management taking into account its complex pathophysiology and targets for treatment.",
author = "Calabr{\`o}, {Rocco Salvatore}",
year = "2012",
language = "English",
isbn = "9781619423169",
pages = "97--127",
booktitle = "Erectile Dysfunction: Causes, Risk Factors and Management",
publisher = "Nova Science Publishers, Inc.",

}

TY - CHAP

T1 - Neurogenic erectile dysfunction

T2 - State of the art!

AU - Calabrò, Rocco Salvatore

PY - 2012

Y1 - 2012

N2 - Erection is a neurovascular event characterised by the tumescence of the cavernous bodies that relies upon integration of neural and humoral mechanisms and requires the participation ofautonomic and somatic nerves and the integration of numerous spinal and supraspinal sites.Erectile dysfunction (ED) is a highly prevalent problem increasing with age, as well as being a major sexual concern for men. Neurogenic ED can be broadly defined as an inability to sustain or maintain a penile erection owing to a neurologic impairment, either centrally or peripherally or both. Neurological disorders may cause an interruption of the long spinal tracts between cortex and sacral cord or the pelvic autonomic nerves interfering with genital engorgement, erection, ejaculation, and climax.They can also challenge the physical ability to embrace, stimulate, engage in intercourse, and maintain urinary and bowel continence during sexual activity. Such factors may lead to a primary or secondary neurogenic ED.Patients with neurological disorders, especially if male and young, might consider their sexual dysfunction as the most devastating aspect. Significant advances in the pharmacological treatment of ED have occurred in recent years, most notably after the introduction of Sildenafil, the first oral selective phosphodiesterase type 5 inhibitor.Nevertheless, many other oral, local and surgical treatments are available and their efficacy and safety depend on the specific cases.This chapter is aimed at evaluating the current advances in neurogenic ED management taking into account its complex pathophysiology and targets for treatment.

AB - Erection is a neurovascular event characterised by the tumescence of the cavernous bodies that relies upon integration of neural and humoral mechanisms and requires the participation ofautonomic and somatic nerves and the integration of numerous spinal and supraspinal sites.Erectile dysfunction (ED) is a highly prevalent problem increasing with age, as well as being a major sexual concern for men. Neurogenic ED can be broadly defined as an inability to sustain or maintain a penile erection owing to a neurologic impairment, either centrally or peripherally or both. Neurological disorders may cause an interruption of the long spinal tracts between cortex and sacral cord or the pelvic autonomic nerves interfering with genital engorgement, erection, ejaculation, and climax.They can also challenge the physical ability to embrace, stimulate, engage in intercourse, and maintain urinary and bowel continence during sexual activity. Such factors may lead to a primary or secondary neurogenic ED.Patients with neurological disorders, especially if male and young, might consider their sexual dysfunction as the most devastating aspect. Significant advances in the pharmacological treatment of ED have occurred in recent years, most notably after the introduction of Sildenafil, the first oral selective phosphodiesterase type 5 inhibitor.Nevertheless, many other oral, local and surgical treatments are available and their efficacy and safety depend on the specific cases.This chapter is aimed at evaluating the current advances in neurogenic ED management taking into account its complex pathophysiology and targets for treatment.

UR - http://www.scopus.com/inward/record.url?scp=84895255588&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895255588&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:84895255588

SN - 9781619423169

SP - 97

EP - 127

BT - Erectile Dysfunction: Causes, Risk Factors and Management

PB - Nova Science Publishers, Inc.

ER -